Hydroxyurea therapy in sickle cell disease: knowledge and prescription patterns among care providers in a low-and middle-income setting
Main Article Content
Keywords
Hydroxyurea, sickle cell disease, knowledge, prescription practices, Low- and middle-income settings , Nigeria
Abstract
Background: Hydroxyurea is a safe, effective, and well-tolerated disease-modifying therapy for patients with sickle cell disease (SCD), leading to reduced morbidity, mortality, and an improved quality of life. However, its underutilization, driven by inadequate knowledge and variability in use among SCD care providers, may limit its benefits. This study assessed the knowledge and prescription patterns of hydroxyurea among SCD care providers in Jos, Nigeria.
Methodology: A cross-sectional survey of 132 physicians managing SCD was conducted to collect data on socio-demographics, hydroxyurea knowledge, and prescription patterns using a proforma. Knowledge was assessed using 17 questions (maximum score: 17). Scores above 12 (50th percentile) were classified as “good,” while scores of 12 or below were categorized as “poor.” Prescription patterns were evaluated against the National Institutes of Health (2014) and British Society for Haematology (2018) guidelines. Data were analyzed using descriptive and inferential statistics.
Results: Sixty-seven (50.8%) of the 132 physicians had inadequate knowledge of hydroxyurea’s clinical benefits and safety. Only 35 (26.5%) were aware of available treatment guidelines, and 32 (24.2%) had ever prescribed hydroxyurea. Among prescribers, nine (28.1%) used inappropriate criteria to initiate treatment and six (18.8%) prescribed below recommended doses. The median maximum daily prescribed dose was 750mg, whereas five (15.6%) physicians did not exceed 200mg, irrespective of patient weight. Treatment guidelines
were not followed by 25 (78.1%) of prescribers.
Conclusion: This study revealed a high prevalence of inadequate knowledge and inconsistent hydroxyurea prescription practices among SCD care providers. Targeted training is essential to enhance hydroxyurea utilization and ensure adherence to standardized treatment guidelines, ultimately improving patient outcomes.
References
2. Piel FB, Hay SI, Gupta S, Weatherall DJ, Williams TN. Global burden of sickle cell anaemia in children under five, 2010–2050: modelling based on demographics, excess mortality, and interventions. PLoS Med. 2013;10: e1001484. doi: 10.1371/journal.pmed.1001484.
3. Chakravorty S, Williams TN. Sickle cell disease: a neglected chronic disease of increasing global health importance. Arch Dis Child. 2015; 100:48–53.
4. Piel FB, Patil AP, Howes RE, Nyangri OA, Gething PW, Dewi M, et al. Global epidemiology of sickle haemoglobin in neonates: A contemporary geostatistical model‐based map and population estimates. Lancet 2013; 381:142–151
5. Odame I. Sickle cell disease in children: an update of the evidence in low- and middle-income settings. Arch Dis Child. 2023;108(2):108-114. doi:10.1136/archdischild-2021-323633.
6. Powars DR, Chan LS, Hiti A, Ramicone E, Johnson C. Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients. Medicine 2005; 84:363–76.
7. Charache S, Terrin ML, Moore RD. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 1995; 332:1317–22.
8. Wang WC, Ware RE, Miller ST, Iyer RV, Casella JF, Minniti CP, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet 2011; 377:1663–72.
9. Ofakunrin AOD, Oguche S, Adekola K, Okpe ES, Afolaranmi TO, Daiku-Akinwumi IN, et al. Effectiveness and Safety of Hydroxyurea in the Treatment of Sickle Cell Anaemia Children in Jos, North Central Nigeria. J. Trop. Pediatr 2020; 66:290–298.
10. Badawy SM, Thompson AA, Lai JS, Penedo FJ, Rychlik K, Liem RI. Health-related quality of life and adherence to hydroxyurea in adolescents and young adults with sickle cell disease. Pediatr Blood Cancer. 2016;64:e26369.
11.Ware RE. How I use hydroxyurea to treat young patients with sickle cell anemia. Blood. 2010;115(26):5300-11. doi: 10.1182/blood-2009-04-146852.
12. National Heart, Lung, and Blood Institute. Evidence-Based Management of Sickle Cell Disease: Expert Panel Report, 2014. Bethesda, MD: National Heart, Lung, and Blood Institute, US Department of Health and Human Services; 2014. Available at: http://www.nhlbi.nih.gov/health-pro/guidelines/sickle-cell-disease-guidelines (20 March 2021, date last accessed).
13. Qureshi A, Kaya B, Pancham S, Keenan R, Anderson J, Akanni M, et al. Guidelines for the use of hydroxycarbamide in children and adults with sickle cell disease. A British Society for Haematology Guideline. BJH 2018, 181, 460–475
14. Federal Ministry of Health, Nigeria. National Guideline for the Control and Management of Sickle Cell Disease. Abuja (Nigeria): Federal Ministry of Health; 2014. Available from: http://www.health.gov.ng/doc/SCDGuideline.pdf (last accessed 10 January, 2025).
15. Brandow AM, Jirovec DL, Panepinto JA. Hydroxyurea in children with sickle cell disease: practice patterns and barriers to utilization. Am J Hematol 2010; 85:611-3
16. Power-Hays A, Ware RE. Effective use of hydroxyurea for sickle cell anemia in low-resource countries. Curr Opin Hematol. 2020; 27(3):172-180.
17. Jekel JF, Katz DL, Elmore JG. Sample size randomization and probability theory. In: Epidemiology, biostatistics, and preventive medicine. Philadelphia: WB Saunders; 2nd edition 2001. p.199.
18. Ofakunrin AO, Okpe ES, Afolaranmi TO, Olaosebikan RR, Kanhu PU, Adekola K et al. Level of utilization and provider-related barriers to the use of hydroxyurea in the treatment of sickle cell disease patients in Jos, North-Central Nigeria. Afr Health Sci. 2021;21(2):765-774.
19. Keikhaei B, Yousefi H, Bahadoram M. Hydroxyurea: clinical and hematological effects in patients with sickle cell anemia. Glob J Health Sci. 2015; 19:252–256.
20. Lanzkron S, Haywood C Jr, Hassell KL, Rand C. Provider barriers to hydroxyurea use in adults with sickle cell disease: a survey of the Sickle Cell Disease Adult Provider Network. J Natl Med Assoc. 2008; 100:968–973
21. Tshilolo L, Tomlinson G, Williams TN, Santos B, Olupot-Olupot P, Lane A, et al. Hydroxyurea for children with sickle cell anemia in sub Saharan Africa. N Engl J Med 2019; 380:121–31
22. Algiraigri AH, Radwi M. Long‐term safety of hydroxyurea in sickle cell anemia and other benign diseases: systematic review and meta‐analysis. Blood 2014; 124, 560.
23. Castro O, Nouraie M, Oneal P. Hydroxycarbamide treatment in sickle cell disease: estimates of possible leukaemia risk and of hospitalization survival benefit. Br J Haematol. 2014;167: 687–691.
24. Brandow AM, Panepinto JA. Hydroxyurea use in sickle cell disease: the battle with low rates of prescription, poor patient compliance, and fears of toxicities and side effects. Exp Rev Hematol 2010; 3:255-60.
25. Elghazaly AA, Aljatham AA, Khan AM, Elneil RM, Jafar SZS, Elwishy SA, et al. Patterns of prescribing hydroxyurea for sickle cell disease patients from a central hospital, Saudi Arabia. Hematol Rep. 2019;11(1):7860.
26. Creary S, Zickmund S, Ross D, Krishnamurti L, Bogen DL. Hydroxyurea therapy for children with sickle cell disease: describing how caregivers make this decision. BMC Res Notes. 2015; 8:372.
27. Inusa BPD, Wale A, Hassan AA, Idhate T, Dogara L, Ijei I, et al. Low-dose hydroxycarbamide therapy may offer similar benefits as maximum tolerated dose for children and young adults with sickle cell disease in low-middle-income settings. F1000Res. 2018; 7: F1000 Faculty Rev-1407.
28. Galadanci NA, Abdullahi SU, Ali AS, Jibir BW, Aminu H, Tijjani A, et al. Moderate fixed-dose hydroxyurea for primary prevention of strokes in Nigerian children with sickle cell disease: Final results of the SPIN trial. Am J Hematol. 2020; 95(9): E247-E250.
29. Paintsil V, Ally M, Isa H, Anie KA, Mgaya J, Nkanyemka M, et al. Development of multi-level standards of care recommendations for sickle cell disease: Experience from SickleInAfrica. Front Genet. 2023; 13:1052179. doi: 10.3389/fgene.2022.1052179.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
This is an open-access journal and articles are distributed under the terms of the Creative Commons Attribution Non-Commercial Share-Alike License 4.0. This licence allows users to download and share, remix, tweak and build upon the article for non-commercial purposes, so long as the original authorship is acknowledged and the new creations are licensed under identical terms.